Citi analyst Joel Beatty downgraded The Medicines Co. to Neutral from Buy with an unchanged price target of $55. The shares are up ~40% since the initial topline Phase 3 results were announced in late August, Beatty tells investors in a research note. After the remaining Phase 3 data by the end of September, the analyst sees a lack of catalysts that would be likely to move the stock price higher over the next year. The September data, which is "likely to be clean and consistent" with the previous Phase 3 data, will only lead to ~0%-10% further upside for the stock, says Beatty.